Home News Content

Takeda Pharmaceuticals announced that it will incur restructuring expenses of 140 billion yen in the 2024 fiscal year

海角七号
134 0 0

Takeda Pharmaceuticals stated that as part of its multi-year plan to support growth and improve profit margins, the company will incur a one-time restructuring fee of 140 billion yen in the 2024 fiscal year, which has been reflected in the full year forecast. Takeda Pharmaceuticals stated that it will include measures to optimize its workforce, and specific details will be provided in& Quota; At the appropriate time& Quota; Decision. (Bloomberg)
Logomoney.com is an information publishing platform that only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

海角七号
  • Follower

    0

  • Follow

    1

  • Article

    29